NICE recommends enzalutamide
The National Institute for Health and Care Excellence has recommended enzalutamide as an option for treating metastatic hormone-relapsed prostate cancer in people who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated, only when the company provides it with the discount agreed in the patient access scheme.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200587
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com